Mylan Inc (NASDAQ:MYL)

CAPS Rating: 4 out of 5

The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.

Recs

0
Player Avatar brenoboyle (73.10) Submitted: 3/1/2013 9:02:46 PM : Outperform Start Price: $28.77 MYL Score: -2.58

Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.

Featured Broker Partners


Advertisement